Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Trial ID or NCT#
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes.This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToStephanie Middleton
Go Back To The Trial